Current position

Fidelity Investments’s Ionis Pharmaceuticals Inc (IONS) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

FMR LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares42.87MHighest verified quarter-end share count
Quarters reported40Verified quarters with shares above zero
What happened?

FMR LLC first reported Ionis Pharmaceuticals Inc in Q3 2016. The reported position was increased and reduced across later filings. FMR LLC currently reports 24.63M shares. The latest verified filing showed: Bought 0.3% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 0.3% more+75.32K shares · 24.63M shares reported after the change
Filing context

Quarter-end price $79.29

Q1 2026
Bought 2.0% more+484.54K shares · 24.56M shares reported after the change
Filing context

Quarter-end price $75.09

Q4 2025
Bought 1.6% more+383.06K shares · 24.07M shares reported after the change
Filing context

Quarter-end price $79.11

Q3 2025
Bought 0.2% more+46.05K shares · 23.69M shares reported after the change
Filing context

Quarter-end price $65.42

Q2 2025
Bought 0.1% more+29.41K shares · 23.64M shares reported after the change
Filing context

Quarter-end price $39.51

Q1 2025
Bought 4.1% more+924.09K shares · 23.61M shares reported after the change
Filing context

Quarter-end price $30.17

1 unchanged quarter is collapsed by default.

Portfolio importance

How important is Ionis Pharmaceuticals Inc in FMR LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#185of 5572 reported positions
Peak portfolio weight0.2%Q1 2019
Best historical rank#91Q1 2019
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$43.812026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$79.29Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

Coverage is bounded to Fidelity’s top reported positions and material events rather than every security in each Form 13F. The consolidated FMR LLC filing includes multiple Fidelity investment managers. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.